Erlotinib in the first-line treatment of non-small-cell lung cancer

breast cancer, early stage

(2012) T. S. K. Mok et al.   ANNALS OF ONCOLOGY

Complex Role of Histone Deacetylase Inhibitors in the Treatment of Non–Small-Cell Lung Cancer

(2012) Joel W. Neal et al.   JOURNAL OF CLINICAL ONCOLOGY

First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial

(2012) Cesare Gridelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer

(2012) Kang-Yi Su et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacogenetic Analysis of BR.21, a Placebo-Controlled Randomized Phase III Clinical Trial of Erlotinib in Advanced Non-small Cell Lung Cancer

(2012) Geoffrey Liu et al.   Journal of Thoracic Oncology

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

(2012) Siow Ming Lee et al.   LANCET ONCOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: A randomized, open-label study

(2012) Y. Sun et al.   LUNG CANCER

A Phase II Trial of Erlotinib As Front-Line Treatment in Clinically Selected Patients With Non–Small-Cell Lung Cancer

(2011) Athanasios G. Pallis et al.   Clinical Lung Cancer

Are We Making Progress in Curing Advanced Cervical Cancer?

(2011) Gillian Thomas   JOURNAL OF CLINICAL ONCOLOGY

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

(2011) Masahiro Fukuoka et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective Molecular Marker Analyses ofEGFRandKRASFrom a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer

(2011) Wolfram Brugger et al.   JOURNAL OF CLINICAL ONCOLOGY

A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer

(2011) Thomas E. Stinchcombe et al.   Journal of Thoracic Oncology

Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non-small Cell Lung Cancer Patients Aged 70 Years or Older

(2011) Yuh-Min Chen et al.   Journal of Thoracic Oncology

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

Phase II study of erlotinib for chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets

(2010) Dae Ho Lee et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Efficacy and Safety of Erlotinib in 1242 East/South-East Asian Patients with Advanced Non-small Cell Lung Cancer

(2010) Tony Mok et al.   Journal of Thoracic Oncology

Erlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study

(2010) Martin Reck et al.   Journal of Thoracic Oncology

Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations

(2010) Yelena Y. Janjigian et al.   Journal of Thoracic Oncology

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

(2010) Federico Cappuzzo et al.   LANCET ONCOLOGY

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?

(2009) Yuri Rukazenkov et al.   ANTI-CANCER DRUGS

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

(2009) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

(2009) Tony S.K. Mok et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer

(2009) Bjørn H. Grønberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial

(2009) Jean-Yves Douillard et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study

(2009) Glenwood D. Goss et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung Cancer

(2009) Rodrigo Arriagada et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase II Study of Erlotinib as Initial Treatment for Patients with Stage IIIB-IV Non-small Cell Lung Cancer

(2009) Wallace Akerley et al.   Journal of Thoracic Oncology

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies

(2009) Chen Mao et al.   LUNG CANCER

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

(2009) Rafael Rosell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

(2009) A F Gazdar   ONCOGENE

Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer

(2008) Amit Kumar et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2

(2008) Rogerio Lilenbaum et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

(2008) Gary M. Strauss et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

(2008) Giorgio Vittorio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY

Southwest Oncology Group Phase II Trial (S0341) of Erlotinib (OSI-774) in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2

(2008) Paul J. Hesketh et al.   Journal of Thoracic Oncology

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

(2008) Helena Linardou et al.   LANCET ONCOLOGY

EGFR Antagonists in Cancer Treatment

(2008) Fortunato Ciardiello et al.   NEW ENGLAND JOURNAL OF MEDICINE